Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum

Regulatory Peptides

Volumn 118, Issue 1-2, 2004, Pages 11-18

  Hansen, Lene ^a   Hartmann, Bolette ^a   Mineo, Hitoshi ^a   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gastrointestinal hormones; Glucagon; Insulin; Regulation of secretion; Somatostatin

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; INSULIN; PEPTIDE YY; PROGLUCAGON; SOMATOSTATIN;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEEDBACK SYSTEM; MOTOR ACTIVITY; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; SMOOTH MUSCLE CONTRACTION; SWINE; TISSUE PERFUSION;

SUIDAE;

EID: 0842346386     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2003.10.021     Document Type: Article

References (49)

1. Holst J.J. Enteroglucagon. Annu. Rev. Physiol. 59:1997;257-271.
2. Eissele R., Goke R., Willemer S., Harthus H.P., Vermeer H., Arnold R.et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 22:1992;283-291.
3. Damholt A.B., Kofod H., Buchan A.M. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res. 298:1999;287-293.
4. Orskov C., Holst J.J., Nielsen O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 123:1988;2009-2013.
5. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., Holst J.J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38:1993;665-673.
6. Layer P., Holst J.J., Grandt D., Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig. Dis. Sci. 40:1995;1074-1082.
7. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R.et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273:1997;E981-E988.
8. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101:1998;515-520.
9. Drucker D.J., Erlich P., Asa S.L., Brubaker P.L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. U. S. A. 93:1996;7911-7966.
10. Hartmann B., Thulesen J., Hare K.J., Kissow H., Orskov C., Poulsen S.S. et al. Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul. Pept. 105:2002;173-179.
11. Orskov C., Holst J.J., Knuhtsen S., Baldissera F.G., Poulsen S.S., Nielsen O.V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 119:1986;1467-1475.
12. Bottcher G., Sjolund K., Ekblad E., Hakanson R., Schwartz T.W., Sundler F. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul. Pept. 8:1984;261-266.
13. Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 89:1985;1070-1077.
14. Wen J., Phillips S.F., Sarr M.G., Kost L.J., Holst J.J. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. Am. J. Physiol. 269:1995;G945-G952.
15. Mortensen K., Christensen L.L., Holst J.J., Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 114:2003;189-196.
16. Orskov C., Holst J.J. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand. J. Clin. Lab. Invest. 47:1987;165-174.
17. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., Marks V. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J. Endocrinol. 138:1993;159-166.
18. Orskov C., Wettergren A., Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 31:1996;665-670.
19. Miholic J., Orskov C., Holst J.J., Kotzerke J., Meyer H.J. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig. Dis. Sci. 36:1991;1361-1370.
20. Roberge J.N., Brubaker P.L. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology. 133:1993;233-240.
21. Herrmann-Rinke C., Voge A., Hess M., Goke B. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J. Endocrinol. 147:1995;25-31.
22. Dumoulin V., Dakka T., Plaisancie P., Chayvialle J.A., Cuber J.C. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology. 136:1995;5182-5188.
23. Plaisancie P., Bernard C., Chayvialle J.A., Cuber J.C. Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. Endocrinology. 135:1994;2398-2403.
24. Damholt A.B., Buchan A.M., Kofod H. Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. Endocrinology. 139:1998;2085-2091.
25. Hansen L., Holst J.J. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno-ileal loop? Regul. Pept. 110:2002;39-45.
26. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91:1993;301-307.
27. Hansen L., Hartmann B., Bisgaard T., Mineo H., Jorgensen P.N., Holst J.J. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am. J. Physiol. 278:2000;E1010-E1018.
28. Baldissera F.G., Nielsen O.V., Holst J.J. The intestinal mucosa preferentially releases somatostatin-28 in pigs. Regul. Pept. 11:1985;251-262.
29. Holst J.J., Jensen S.L., Nielsen O.V., Schwartz T.W. Oxygen supply, oxygen consumption, and endocrine and exocrine secretions of the isolated, perfused, porcine pancreas. Acta Physiol. Scand. 109:1980;7-13.
30. Schmidt P.T., Holst J.J. Use of antagonists to define tachykininergic control of intestinal motility in pigs. Peptides. 18:1997;373-379.
31. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 43:1994;535-539.
32. Baldissera F.G., Munoz-Perez M.A., Holst J.J. Somatostatin 1-28 circulates in human plasma. Regul. Pept. 6:1983;63-69.
33. Krarup T., Holst J.J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul. Pept. 9:1984;35-46.
34. Hartmann B., Johnsen A.H., Orskov C., Adelhorst K., Thim L., Holst J.J. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides. 21:2000;73-80.
35. Sheikh S.P., Holst J.J., Orskov C., Ekman R., Schwartz T.W. Release of PYY from pig intestinal mucosa; luminal and neural regulation. Regul. Pept. 26:1989;253-266.
36. Creutzfeldt W., Talaulicar M., Ebert R., Willms B. Inhibition of gastric inhibitory polypeptide (GIP) release by insulin and glucose in juvenile diabetes. Diabetes. 29:1980;140-145.
37. Orskov C., Jeppesen J., Madsbad S., Holst J.J. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 87:1991;415-423.
38. Toft-Nielsen M.B., Damholt M.B., Madsbad S., Hilsted L.M., Hughes T.E., Michelsen B.K.et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 86:2001;3717-3723.
39. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76:1993;912-917.
40. Nauck M.A., Busing M., Orskov C., Siegel E.G., Talartschik J., Baartz A.et al. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol. 30:1993;39-45.
41. Brubaker P.L. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology. 128:1991;3175-3182.
42. Balks H.J., Holst J.J., von zur M., Brabant G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J. Clin. Endocrinol. Metab. 82:1997;786-790.
43. Schmidt P.T., Rickelt L.F., Holst J.J. Tachykinins stimulate release of peptide hormones (glucagon-like peptide-1) and paracrine (somatostatin) and neurotransmitter (vasoactive intestinal polypeptide) from porcine ileum through NK-1 receptors. Dig. Dis. Sci. 44:1999;1273-1281.
44. Francis B.H., Baskin D.G., Saunders D.R., Ensinck J.W. Distribution of somatostatin-14 and somatostatin-28 gastrointestinal-pancreatic cells of rats and humans. Gastroenterology. 99:1990;1283-1291.
45. Chisholm C., Greenberg G.R. Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am. J. Physiol. Endocrinol. Metab. 283:2002;E311-E317.
46. Harbeck M.C., Louie D.C., Howland J., Wolf B.A., Rothenberg P.L. Expression of insulin receptor mRNA and insulin receptor substrate 1 in pancreatic islet beta-cells. Diabetes. 45:1996;711-717.
47. Toft-Nielsen M.B., Madsbad S., Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 22:1999;1137-1143.
48. Deacon C.F., Wamberg S., Bie P., Hughes T.E., Holst J.J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol. 172:2002;355-362.
49. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E.et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110:2002;43-52.